Fig. 4.

eAmSPC are efficacious in murine Mabs infection models. (A) Schematic of proof-of-concept studies investigating in vivo efficacy of lead eAmSPCs and AMK in an acute (Top; B and C) and chronic (Bottom; D and E) models of infection. (B and C) Bacterial counts in the (B) lungs and (C) spleens of SCID mice in the acute infection model. (D and E) Bacteria counts in the (D) lungs and (E) spleens of SCID mice in the chronic infection model. Results shown as mean ± SEM, n = 3 biological replicates at day 1 (and day 27 for chronic model) or six biological replicates at endpoint for all treatment conditions with the limit of detection being Log10 CFU of 1.7. Statistical significance using ANOVA and Dunnett multiple comparison test with calculated P-values shown. Abbreviations: AMK, amikacin; LOD, limit of detection; SCID, severe combined immune deficiency.